The FDA's approval of Rezdiffra exceeded analysts' expectati...

The FDA's approval of Rezdiffra exceeded analysts' expectations. The absence of a liver biopsy requirement in Rezdiffra's label is expected to positively impact biotech stocks with exposure to MASH.